Drugs / Alpha-proteinase inhibitor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05485155 | May 2025 → Oct 2026 expected | eosinophilic esophagitis | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-proteinase inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05485155 ↗ |
| Route | Intravenous | “Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.” NCT05485155 ↗ |